Kite’s Yescarta Is First CAR-T To Move Into Second-Line Lymphoma

 
• By Joseph Haas
Cancer cell therapy
Kite obtains first second-line cancer indication for a CAR-T therapeutic • Source: Alamy

More from New Products

More from Scrip